Tharimmune Inc. (THAR NASDAQ) stock market data APIs
$1.8614
-0(-0%)
as of July 3, 2025
Try our APIs with
free plan!
Tharimmune Inc. Financial Data Overview
Price chart is built with
Anychart
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Prev. Close
1.8614
Open
1.8597
High
1.887
Low
1.7304
52 wk Range
0.952-4.4053
Market Cap
7 834 K
Shares Outstanding
4 212 K
EPS
-0.99
Beta
1.063
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tharimmune Inc. data using free add-ons & libraries
Get Tharimmune Inc. Fundamental Data
Tharimmune Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tharimmune Inc. News
New
Tharimmune executive chairman buys $500,000 in shares
Gravitas Capital LP, Executive Chairman at Tharimmune, Inc. (NASDAQ:THAR), has recently purchased 337,838 shares of common stock at a price of $1.48, according to a Form 4 filing with the Securities a...
Tharimmune director Parikh buys $1,450 in company stock
Director Sanam Parikh of Tharimmune, Inc. (NASDAQ:THAR), a micro-cap biotech company with a market capitalization of $3.57 million, recently purchased 1,000 shares of the company’s common stock. Acc...
Tharimmune CEO Appajosyula buys shares worth $90,972
Tharimmune, Inc. (NASDAQ:THAR) Chief Executive Officer Sireesh Appajosyula reported purchasing shares of the company’s common stock on June 20, 2025. The transactions involved the acquisition of 61,...
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
